Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03153462
Title Axicabtagene Ciloleucel Expanded Access Study
Acronym ZUMA-9
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Kite Pharma, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Duarte California 91010 United States Details
Stanford Cancer Institute Stanford California 94305 United States Details
University of Miami Hospital and Clinics Miami Florida 33136 United States Details
H. Lee Moffitt Cancer and Research Institute Tampa Florida 33612 United States Details
University of Chicago Medical Center Chicago Illinois 60637 United States Details
The University of Kansas Hospital Investigational Drug Services Westwood Kansas 66205 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
University of Nebraska Medical Center Omaha Nebraska 68198 United States Details
Roswell Park Cancer Institute Buffalo New York 14263 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Cleveland Clinic Cleveland Ohio 44195 United States Details
James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
University of Washington Medical Center Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field